Theravance Biopharma's velusetrag (TD-5108) has been granted Fast Track designation by the U.S. Food and Drug Administration. Read More »

Kite Pharma recently presented the results of its ZUMA-1 clinical trial involving axicabtagene ciloleucel (KTE-C19) at the American Society of Hematology (ASH) 58th Annual Meeting. Read More »

Merck Research Laboratories President Dr. Roger Perlmutter participated in the Citi 2016 Global Healthcare Conference Wednesday in New York. Read More »

Endo International and BioDelivery Sciences International (BDSI) have agreed to return the BELBUCA buccal film product to BDSI. Read More »

Baxter International Inc. recently announced the recipients of its seventh annual Leadership Excellence Awards in Pharmacy at the American Society of Health-System Pharmacists 2016 Midyear Meeting. Read More »

Baxter International Inc. has once again earned the highest possible score of 100 percent on the 2017 Corporate Equality Index, which is produced by the Human Rights Campaign Foundation. Read More »

ViiV Healthcare CEO Dr. Dominique Limet will relinquish his title and step down in March. Read More »

Sandoz's generic version of Latisse, bimatoprost ophthalmic solution, 0.03 percent, is now available in the United States. Read More »

Pfizer and its partner Avillion LLP have announced the results from the BFORE clinical study. Read More »

Pfizer will expand its Advancing Science through Pfizer Investigator Research Exchange program next year. Read More »

Endo International plc subsidiary Par Pharmaceutical has released mycophenolate mofetil hydrochloride as an injection in the United States after the Food and Drug Administration gave its approval of Endo’s Abbreviated New Drug Application. Read More »

Merck recently released updated data from its Phase 1b KEYNOTE-028 clinical trial, which involved KEYTRUDA. Read More »

Merck has released updated data from two clinical trials designed to assess KEYTRUDA (pembrolizumab), its anti-PD-1 therapy developed to treat patients who have relapsed or refractory classical Hodgkin lymphoma (cHL). Read More »

Teva Pharmaceuticals Industries has appointed Dipanker Bhattacharjee president and CEO of its Global Generic Medicines Group, effective immediately. Read More »

Eiger BioPharmaceuticals has announced clinical and regulatory development advancements of exendin 9-39, which was developed to treat post-bariatric hypoglycemia. Read More »

A Walgreens study conducted in collaboration with the Scripps Translational Science Institute demonstrated that long-term health engagement can be meaningfully improved by automated health tracking. Read More »

Merck continued its release of KEYTRUDA results by reporting that its Phase 3 KEYNOTE-024 clinical trial demonstrated positive health-related quality of life. Read More »

Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma. Read More »

CVS Health has launched Transform Diabetes Care, its new program set up to assist pharmacy benefits management clients in the improvement of member health outcomes, to decrease costs with aggressive trend management, and to cut medical costs by refining medication adherence. Read More »

Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States. Read More »